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Summary
Background:  Disruption  of  vulnerable  plaques  causes  acute  coronary  syndrome  and  stenosis
progression.  Yellow  plaques  are  regarded  as  vulnerable  and  the  number  of  yellow  plaques  per
vessel (NYP)  has  been  reported  as  a  marker  of  vulnerable  patients.  Therefore,  we  examined  if
patients with  more  yellow  plaques  would  have  higher  risk  of  stenosis  progression.
Methods  and  results:  A  series  of  patients  (n  =  70)  who  received  percutaneous  coronary  interven-
tion (PCI)  and  angioscopy  was  included.  Patients  were  divided  into  2  groups  according  to  NYP:
group 1  (NYP  <  4,  n  =  32)  and  group  2  (NYP  ≥  4,  n  =  38).  Coronary  artery  stenosis  progression  in
any segment  excluding  target  lesion  of  PCI  was  examined  by  angiography  at  7  months.  Maximum
yellow color  grade  of  yellow  plaques  (2.7  ±  0.7  vs.  1.7  ±  1.2,  p  <  0.0001)  and  the  number  of  non-
target disrupted  yellow  plaques  was  larger  in  group  2  than  in  group  1  (1.1  ±  1.5  vs.  0.2  ±  0.6,
p =  0.0017).  Progression  of  coronary  stenosis  was  detected  more  frequently  in  group  2  than  in
group 1  (29%  vs.  9%,  p  =  0.041).  The  number  of  sites  with  stenosis  progression  was  larger  in  group
2 than  in  group  1  (0.47  ±  0.98  vs.  0.09  ±  0.30  sites/patient,  p  =  0.036).
Conclusions:  Vulnerable  patients  with  more  yellow  plaques  had  higher  incidence  of  stenosis
progression.  Approximately  30%  of  vulnerable  patients  with  NYP  ≥  4  had  stenosis  progression
within 7  months.
f  Car© 2011  Japanese  College  o∗ Corresponding author. Tel.: +81 6 6771 6051;
ax: +81 6 6775 2845.
E-mail address: ueda@oph.gr.jp (Y. Ueda).
I
D
p
s
s
914-5087/$ — see front matter © 2011 Japanese College of Cardiology.
oi:10.1016/j.jjcc.2011.04.002diology.  Published  by  Elsevier  Ltd.  All  rights  reserved.
ntroductionisruption  of  lipid-rich  plaques  and  subsequent  thrombosis
lay  a  major  role  both  in  the  development  of  acute  coronary
yndrome  (ACS)  and  in  the  progression  of  coronary  artery
tenosis  [1—9]. Yellow  color  intensity  of  coronary  plaques  is
 Published by Elsevier Ltd. All rights reserved.
 of  s
A
T
J
A
c
a
v
v
s
i
n
s
p
l
o
(
w
a
l
a
w
p
w
o
o
l
i
b
t
a
a
9
A
p
A
s
a
P
n
w
a
m
t
f
b
p
t
a
o
t
u
iPatients  with  more  coronary  yellow  plaques  have  higher  risk
known  to  be  determined  by  the  thickness  of  ﬁbrous  cap,  and
yellow  plaques  are  regarded  as  vulnerable  plaques  [10—12].
The  formation  of  atherosclerotic  plaques  is  known  to  be
a  pan-coronary  process  [13,14],  and  the  number  of  yellow
plaques  per  vessel  has  been  demonstrated  as  a  risk  for  future
ACS  events  [15], i.e.  a  marker  of  vulnerable  patients.  There-
fore,  in  the  present  study,  we  tested  if  the  patients  with
more  yellow  plaques  per  vessel  (more  vulnerable  patients)
would  have  a  higher  risk  of  stenosis  progression  clearly  iden-
tiﬁed  on  the  angiogram.
Methods
Study  patients
A  series  of  consecutive  patients  (n  =  70)  who  received  per-
cutaneous  coronary  intervention  (PCI)  due  to  stable  angina,
silent  myocardial  ischemia,  unstable  angina,  or  acute
myocardial  infarction  and  successful  angioscopic  examina-
tion  of  the  target  vessel  of  PCI  in  our  hospital  was  included.
All  patients  received  PCI  of  only  one  target  vessel  that
was  regarded  as  the  main  culprit  vessel  of  the  disease.
The  culprit  vessel  was  determined  in  an  ordinary  clinical
process  taking  into  consideration  all  the  available  exam-
inations  such  as  electrocardiogram,  echocardiogram,  and
various  stress  tests.  The  patients  who  had  coronary  artery
unsuitable  for  angioscopic  examination  were  not  included.
Follow-up  angiography  was  performed  at  7  months  after  PCI.
The  number  of  yellow  plaques  per  vessel  in  the  target  vessel
of  PCI  was  determined  at  baseline.  Progression  of  coronary
artery  stenosis  was  judged  on  the  baseline  and  follow-up
angiogram.
Intravenous  heparin  (100  U/kg)  was  administered  at
the  beginning  of  catheterization,  and  an  additional
dose  was  repeated  at  the  time  of  PCI  as  a  routine
protocol  in  our  hospital.  Glycoprotein-IIb/IIIa  inhibitors
were  not  used  for  anyone,  because  they  were  not
approved  in  Japan.  Anti-platelet  therapy  was  performed
with  ticlopidine  (200  mg/day)  or  clopidogrel  (75  mg/day)
and  aspirin  (100  mg/day).  Aspirin  was  continued  for-
ever  and  dual  anti-platelet  therapy  was  strongly  rec-
ommended  >1  month  for  bare  metal  stent-  and  >12
months  for  drug-eluting  stent-implanted  patients  as
far  as  they  had  no  contraindication.  Catheterization
was  performed  by  femoral,  brachial,  or  radial  artery
approach  using  a  6  or  7Fr  sheath  and  catheters.  Coro-
nary  angiogram  was  recorded  and  analyzed  by  the
Advantx  medical  system  (GE  Healthcare  Japan,  Tokyo,
Japan).
Hypertensive  patients  in  this  study  were  deﬁned
as  the  patients  with  blood  pressure  ≥140/90  mmHg  or
those  already  taking  anti-hypertensive  drugs.  Hypercholes-
terolemic  patients  in  this  study  were  deﬁned  as  the
patients  with  fasting  serum  total  cholesterol  ≥220  mg/dL  or
those  already  taking  lipid-lowering  drugs.  Diabetic  patients
were  deﬁned  as  the  patients  with  fasting  blood  glucose
≥126  mg/dL  or  those  already  taking  drugs  for  diabetes
mellitus.  Informed  written  consent  was  obtained  from  all
patients.  This  protocol  was  approved  by  the  Osaka  Police
Hospital  Ethical  Committee.
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ngioscopic  examination  and  evaluation
he  angioscope  RX-3310A  &  MV-5010A  (Machida,  Tokyo,
apan)  and  optic  ﬁber  DAG-2218LN  (Machida)  were  used.
ngioscopic  observations  were  made  while  blood  was
leared  away  from  view  by  the  injection  of  3%  dextran-40
s  we  previously  reported  [3].
Angioscopic  examination  was  performed  in  the  target
essel  of  PCI;  and  the  number  of  yellow  plaques  in  the
essel  was  deﬁned  as  the  number  of  yellow  plaques  per  ves-
el  as  we  previously  reported  [15]. We  divided  the  patients
nto  group  1  (the  number  of  yellow  plaques  per  vessel  <  4,
 =  32)  and  group  2  (the  number  of  yellow  plaques  per  ves-
el  ≥4,  n  =  38)  according  to  the  number  of  yellow  plaques
er  vessel.  We  divided  the  patients  by  the  number  of  yel-
ow  plaques  =  4  to  make  2  groups  of  similar  size.  The  color
f  each  yellow  plaque  detected  was  classiﬁed  into  3  grades
1,  slight  yellow;  2,  yellow;  3,  intensive  yellow)  comparing
ith  the  standard  colors  as  we  have  previously  reported  [11],
nd  the  maximum  yellow  color  grade  of  all  detected  yel-
ow  plaques  was  determined  for  each  patient.  Presence  or
bsence  of  thrombus  in  the  target  and  non-target  segments
as  also  evaluated,  and  the  number  of  disrupted  yellow
laques  in  the  non-target  segments  was  counted.  Thrombus
as  deﬁned  as  white  or  red  material  that  had  cotton-like
r  ragged  appearance  or  that  presented  fragmentation  with
r  without  protrusion  into  the  lumen  or  adherent  to  the
uminal  surface.  Yellow  plaques  were  deﬁned  as  disrupted
f  they  had  thrombus.  Angioscopic  images  were  interpreted
y  2  specialists  of  angioscopy,  and  in  case  of  disagreement
he  3rd  reviewer  determined  the  evaluation.  The  inter-
nd  intra-observer  reproducibility  for  the  interpretation  of
ngioscopic  images  was  85%  and  95%  for  plaque  color,  and
0%  and  100%  for  thrombus,  respectively.
ngiographic  evaluation  of  coronary  stenosis
rogression
mong  the  angiographic  views  recorded  at  baseline,  one
uitable  view  for  quantitative  coronary  angiography  (QCA)
nalysis  was  determined  for  each  major  coronary  vessel.
rior  to  angiography,  all  patients  received  intra-coronary
itroglycerine  injection.  The  same  angiographic  view  that
as  used  at  baseline  for  each  vessel  was  also  used  for  the
nalysis  at  follow-up,  and  coronary  branches  were  used  as
arkers  to  identify  coronary  segments.  In  each  projection,
he  catheter  tip  not  ﬁlled  with  contrast  medium  was  used
or  calibration.  All  coronary  sites  that  look  stenotic  either  at
aseline  or  at  follow-up  were  analyzed  by  QCA  to  measure
ercent  stenosis  and  minimum  lumen  diameter  (MLD).  The
arget  lesions  of  PCI  were  excluded  from  the  analysis.  QCA
nalysis  was  done  blinded  to  the  patients’  characteristics  by
ne  specialist  of  coronary  artery  catheterization.  We  deﬁned
he  progression  of  stenosis  as  [percent  stenosis  at  follow-
p  (%)]  −  [percent  stenosis  at  baseline  (%)]  >  20%  [16]. The
ncidence  of  stenosis  progression  and  the  number  of  sites
ith  stenosis  progression  were  compared  between  groups  1
nd  2.  Furthermore,  multivariate  logistic  regression  analysis
as  performed  to  clarify  the  factors  that  contributed  to  the
tenosis  progression.
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Figure  1  A  representative  case  explaining  the  method  to  evaluate  the  progression  of  coronary  artery  stenosis.  Baseline  (A  and
C) and  follow-up  (B  and  D)  angiogram  are  presented.  Left  circumﬂex  coronary  artery  received  balloon  angioplasty  (target  lesion  is
indicated by  red  line  with  arrows)  and  angioscopic  examination  (observed  segment  is  indicated  by  white  line  with  arrow).  Six  yellow
plaques were  detected  (yellow  arrows)  by  angioscopy.  The  segments  that  looked  stenotic  (a,  b,  c,  d,  e,  f,  and  h)  at  baseline  were
analyzed by  quantitative  coronary  angiography  (QCA)  both  at  baseline  and  at  follow-up.  Furthermore,  the  segment  that  looked
stenotic at  follow-up  (g)  was  also  analyzed  both  at  baseline  and  at  follow-up.  The  segment  that  received  percutaneous  coronary
intervention was  excluded  from  QCA  analysis.  Diameter  stenoses  measured  by  QCA  are  presented  in  Table  3.  Progression  of  diameter
stenosis was  detected  at  segments  d  and  g  (For  interpretation  of  references  to  color  in  this  ﬁgure  legend,  the  reader  is  referred  to
the web  version  of  this  article.).
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ontinuous  data  are  presented  as  mean  ±  SD.  While  differ-
nces  of  normally-distributed  continuous  variables  between
roups  were  compared  by  Student’s  t-test,  discrete  vari-
bles  and  nonnormally-distributed  variables  were  compared
y  Mann—Whitney  U  test.  Categorical  variables  were  com-
ared  by  the  chi-square  test.  A  multivariate  stepwise
egression  analysis  was  used  to  assess  whether  number  of
ellow  plaques  per  vessel  was  independently  associated
ith  progression  of  coronary  artery  stenosis  at  the  follow-
p.  The  variables  included  in  this  analysis  were  current
moking,  multi-vessel  disease,  beta-blocker  use,  number
f  yellow  plaques  per  vessel,  maximum  color  grade  of
ellow  plaques,  and  number  of  disrupted  yellow  plaques
t  non-target  segments  per  vessel.  A  p-value  <  0.05  was
egarded  as  statistically  signiﬁcant.  Analysis  was  done  with
b
s
lPSS  version  16.0J  for  Windows  (SPSS  Inc.,  Chicago,  IL,
SA).
esults
atients’  characteristics
atients’  characteristics  are  presented  in  Table  1.  Among
0  patients  included,  no  adverse  cardiac  event  (death,  ACS,
CI  of  non-target  lesion,  and  coronary  artery  bypass  graft)
ccurred  during  the  follow-up  interval  of  212  ±  103  days.
hree  patients  received  re-PCI  of  the  original  target  lesion
ecause  of  restenosis.
Although  MLD  and  mean  diameter  stenosis  of  all  analyzed
ites  were  not  different  between  groups  2  and  1  at  base-
ine,  the  maximum  yellow  color  grade  and  the  number  of
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Table  1  Patients’  characteristics.
All  Group  1  Group  2  p-value
(NYP<4)  (NYP≥4)
Number  of  patients  70  32  38
Age, years  60  ±  15  59  ±  12  60  ±  18  0.85
Male gender,  n  (%)  63  (90)  30  (94)  33  (87)  0.34
Coronary risk  factors,  n  (%)
Hypertension  39  (56)  14(44)  25  (66)  0.066
Hypercholesterolemia 61  (87)  28  (88)  33  (87)  0.94
Diabetes mellitus 26  (37) 13(41)  13(34)  0.58
Current smoking 42  (60) 24  (75) 18(47) 0.020
Serum lipid  levels,  mg/dL
Total  cholesterol 203  ±  38 205  ±  43 200  ±  32 0.41
LDL cholesterol  127  ±  35  126  ±  40  129  ±  31  0.45
HDL cholesterol  46  ±  9  46  ±  9  46  ±  8  0.47
Triglyceride  148  ±  76  167  ±  80  130  ±  68  0.14
Hemoglobin  A1c,  %  5.8  ±  1.1  5.6  ±  1.1  6.1  ±  1.0  0.59
Body mass  index  24.2  ±  3.0  24.2  ±  2.9  24.1  ±  3.1  0.90
History of  prior  MI,  n  (%)  14(20)  8(25)  6(16)  0.34
Multivessel disease*,  n  (%)  22(31)  14(44)  8(21)  0.043
Diagnosis at  baseline,  n  (%)
Stable  angina  7(10)  3(9)  4(11)  0.87
Silent myocardial  ischemia  9(13)  4(13)  5(13)  0.94
Unstable angina  19(27)  8(25)  11  (29)  0.71
Acute MI 35  (50)  17(53)  18(47)  0.63
Medications,  n  (%)
ACE  inhibitors  or  ARB 43(61)  22  (69)  21  (55)  0.25
Antiplatelet  agents  70(100)  32(100)  38(100)
Beta-blockers 14(20)  10(31)  4(11)  0.03
Calcium antagonists 33  (47) 12(38)  21  (55)  0.14
Nitrates 40 (57) 16(50) 24  (63)  0.27
Statins 52 (74) 24  (75)  28  (74)  0.90
Follow-up interval,  days 212  ±  103 198  ±  37 225  ±  137  0.85
Values are expressed as mean ± SD. ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; LDL, low-density lipopro-
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* Multivessel disease was deﬁned as having ≥2 coronary vessels 
disrupted  yellow  plaques  at  non-target  segments  per  vessel
was  larger  in  group  2  than  in  group  1  (Table  2).
Progression  of  coronary  artery  stenosis
A  representative  case  is  presented  in  Fig.  1  and  Table  3.  MLD
was  not  different  between  groups  1  and  2  at  both  baseline
and  follow-up.  Mean  diameter  stenosis  was  not  different  at
baseline  but  was  larger  in  group  2  than  in  group  1  at  follow-
up  (Table  2).  Progression  of  coronary  artery  stenosis  (Fig.  2)
was  detected  more  frequently  in  group  2  than  in  group  1
(29%  vs.  9%,  p  =  0.041).  More  sites  of  stenosis  progression
were  detected  in  group  2  than  in  group  1  (0.47  ±  0.98  vs.
0.09  ±  0.30  sites/patient,  p  =  0.036).
In  addition,  the  number  of  sites  with  stenosis  progres-
sion  was  21;  and  we  could  observe  7  of  those  21  sites  by
angioscopy  and  detected  yellow  plaques  in  all  of  them.
Multivariate  logistic  regression  analysis  revealed  that  the
number  of  yellow  plaques  per  vessel  (odds  ratio  1.65,  95%
conﬁdence  interval  1.08—2.52,  p  =  0.020)  was  the  only  one
independent  risk  for  stenosis  progression  among  current
smoking,  multi-vessel  disease,  beta-blocker  use,  number  of
a
H
c number of yellow plaques per vessel.
>50% diameter stenosis by angiography.
ellow  plaques  per  vessel,  maximum  color  grade  of  yellow
laques,  and  number  of  disrupted  yellow  plaques  at  non-
arget  segments  per  vessel  (Table  4).
iscussion
e  have  demonstrated  in  the  present  study  that  more  vul-
erable  patients  with  larger  number  of  yellow  plaques  per
essel  have  a  higher  risk  of  coronary  artery  stenosis  progres-
ion.  Actually,  approximately  30%  of  patients  with  ≥4  yellow
laques  per  vessel  had  stenosis  progression  within  7  months.
o  the  best  of  our  knowledge,  this  would  be  the  ﬁrst  report
hat  revealed  the  higher  incidence  of  coronary  artery  steno-
is  progression  in  the  more  vulnerable  patients  determined
y  angioscopy.
revious  reports  on  the  progression  of  coronary
rtery stenosis
ypertension,  hypercholesterolemia,  diabetes  mellitus,  and
urrent  smoking  are  known  [17—20]  to  enlarge  lipid-rich
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Table  2  Angiographic  and  angioscopic  analysis.
All  Group  1  Group  2  p-value
(NYP<4)  (NYP≥4)
Angioscopic  examination
Observed  vessel,  n  (%)  0.045
LAD 33  (47)  10  (31)  23  (60)
LCX 28  (40)  16  (50)  12  (32)
RCA 9  (13)  6  (19)  3  (8)
Observed  vessel  length,  mm 61.6±12.4 60.9±12.0  62.3±12.8  0.65
Number of  yellow  plaques  per  vessel 3.5±2.1 1.6±1.2 5.2±1.0  <0.0001
Maximum color  grade  of  yellow  plaques 2.2±1.1 1.7±1.2 2.7±0.7 0.0006
Thrombus  at  target  lesion  of  PCI,  n  (%) 45  (64) 17  (53) 28  (74) 0.062
Number of  disrupted  yellow  plaques  at  non-target  segments  per  vessel  0.7±1.2  0.2±0.6  1.1±1.5  0.0028
Coronary stenosis  analysis
Number  of  sites  analyzed  by  QCA,  sites  per  patient
All vessels  2.0±0.2  1.6±0.3  2.4±0.2  0.032
LAD 0.6±0.1  0.4±0.1  0.7±0.1  0.052
LCX 0.7±0.1  0.5±0.1  0.8±0.1  0.10
RCA 0.8±0.1  0.7±0.1  0.9±0.1  0.076
Minimum lumen  diameter,  mm
Baseline  1.66±0.48  1.54±0.57  1.74±0.71  0.12
Follow-up 1.49±0.49  1.45±0.59  1.51±0.52  0.62
Mean diameter  stenosis,  %
Baseline  33.0±16.7  31.5±21.2  34.2±11.9  0.51
Follow-up 38.4±19.3  32.4±21.9  43.4±15.4  0.016
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percutaneous coronary intervention; QCA, quantitative coronary 
oronary  plaques  and  increase  their  vulnerability.  However,
hose  classical  coronary  risk  factors  have  not  been  asso-
iated  with  the  progression  of  coronary  artery  stenosis  in
uch  a  short  period  as  7  months.  Presence  of  yellow  color
s  regarded  as  the  direct  marker  of  vulnerable  plaques
11,12,21], and  disruption  of  those  vulnerable  plaques
ollowed  by  thrombus  formation  and  its  organization  is  sup-
osed  to  contribute  to  the  progression  of  luminal  stenosis
6—9];  and  actually,  ruptured  yellow  plaques  detected  by
ngioscopy  in  the  non-culprit  segments  are  known  to  cause
f
h
p
b
igure  2  Incidence  of  coronary  artery  stenosis  progression  (A),  an
er patient  (B).  Signiﬁcantly  higher  incidence  of  coronary  artery  sten
tenosis progression  per  patient  were  detected  in  group  2  comparedonary artery; NYP, the number of yellow plaques per vessel; PCI,
graphy; RCA, right coronary artery.
tenosis  progression  [6].  According  to  an  angiographic  study
22],  patients  with  multivessel  coronary  artery  disease  at  the
ime  of  1st  PCI  were  more  likely  to  require  another  PCI  of
ther  segments  during  1-year  follow-up,  and  the  majority
f  lesions  that  required  subsequent  PCI  had  ≤60%  steno-
is  at  the  time  of  1st  PCI.  Three  established  risk-scores
or  primary  prevention,  i.e.  PROCAM,  SCORE,  and  Framing-
am,  have  positive  linear  relationship  with  the  extent  of
laque  progression  and  lumen  stenosis  progression  measured
y  intravascular  ultrasound  (IVUS)  [23]. However,  there  has
d  the  number  of  sites  with  coronary  artery  stenosis  progression
osis  progression  and  larger  number  of  sites  with  coronary  artery
 with  group  1.
Patients  with  more  coronary  yellow  plaques  have  higher  risk  of  s
Table  3  Coronary  artery  stenosis  in  the  case  presented  in
Fig. 1.
Analyzed  site Diameter  stenosis  analyzed  by  QCA
Baseline  (%) Follow-up  (%)
a 13.5 12.1
b 25.7 33.9
c  19.0  17.8
d 6.8  39.9*
e  22.2  19.3
f 14.7  13.8
g 7.4  55.5*
h 34.4  33.9
QCA, quantitative coronary angiography.
* Progression of stenosis deﬁned as [stenosis at follow-up
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also  reduce  the  risk  of  coronary  artery  stenosis  progression.
Conﬁrmation  of  pathologic  ﬁndings  and  new  ﬁndings(%)] − [stenosis at baseline (%)] >20%.
been  no  report  that  IVUS  can  predict  the  progression  of
coronary  artery  stenosis.
Considering  the  ﬁndings  in  those  reports,  each  of  the
risk  factors  and  the  markers  of  atherosclerosis  extension
may  be  weakly  associated  with  the  risk  of  coronary  artery
stenosis  progression;  however,  the  vulnerable  plaques,  i.e.
yellow  plaques,  may  be  more  directly  associated  with  the
progression  of  coronary  artery  stenosis.  Because  yellow
plaques  would  be  formed  as  a  result  of  multiple  well-known
coronary  risk  factors  such  as  diabetes  mellitus,  hypercholes-
terolemia,  and  hypertension  and  other  unknown  factors  that
promote  the  progression  of  atherosclerosis,  the  number  of
yellow  plaques  would  be  only  weakly  associated  with  each
of  these  risk  factors.  Indeed,  the  factors  that  should  be  asso-
ciated  with  the  number  of  yellow  plaques  were  not  actually
different  between  the  two  groups  in  the  present  study.  Fur-
thermore,  we  have  demonstrated  in  the  present  study  that
the  patients  with  larger  number  of  yellow  plaques  per  ves-
sel  also  have  more  disrupted  yellow  plaques  that  have  been
shown  to  increase  stenosis.  A  possible  explanation  for  why
the  maximum  yellow  color  grade  and  the  number  of  dis-
rupted  yellow  plaques  at  non-target  segments  per  vessel
were  not  identiﬁed  as  independent  risks  for  stenosis  progres-
sion  in  the  present  study  would  be  that  not-yet-disrupted
yellow  plaques  may  also  have  a  chance  to  cause  stenosis
progression  by  disruption  as  well  as  the  already  disrupted
yellow  plaques  and  that  yellow  plaques  of  any  yellow  color
grade  may  have  a  chance  to  disrupt  because  it  has  been
i
i
Table  4  Multivariate  analysis  of  factors  associated  with  progress
Characteristic  
Current  smoking  
Multi-vessel  disease*
Beta-blocker  
Number of  yellow  plaques  per  vessel  
Maximum color  grade  of  yellow  plaques  
Number of  disrupted  yellow  plaques  at  non-target  segments  per  ve
CI, conﬁdence interval.
* Multivessel disease was deﬁned as having ≥2 coronary vessels with tenosis  progression  within  7  months  51
eported  by  optical  coherence  tomography  (OCT)  study  that
ather  thick  ﬁbrous  cap  can  disrupt  and  cause  ACS  [24].
ngioscopically-determined  vulnerable  patients
e  have  previously  reported  using  angioscopy  that  the
umber  of  yellow  plaques  per  vessel  in  a  coronary  artery
s  not  different  between  infarct-related  and  infarct-non-
elated  coronary  arteries,  suggesting  that  formation  of
ellow  plaques  may  progress  equally  in  three  major  coronary
rteries  [14]. Therefore,  the  extent  of  coronary  atheroscle-
osis  and  the  risk  of  coronary  artery  stenosis  progression  may
e  evaluated  by  observing  any  one  of  three  major  coronary
rteries.
The  number  of  yellow  plaques  per  vessel  rather  than  each
ne  of  known  coronary  risk  factors  is  more  strongly  associ-
ted  with  the  future  risk  of  ACS  events  [15]  and  is  regarded
s  a  marker  of  vulnerable  patients.  Although  coronary  risk
actors  are  supposed  to  be  associated  with  the  number  of
ellow  plaques,  the  combination  of  those  and  other  known
nd  unknown  factors  would  play  a role  for  the  formation  of
ellow  plaques  and  each  one  of  them  might  have  only  weak
ssociation  with  the  number  of  yellow  plaques.  Actually,  in
he  present  study,  the  frequencies  of  coronary  risk  factors
isted  in  Table  1  were  not  necessarily  different  between  the
wo  groups.
As  our  previous  report  [15]  has  demonstrated  that  the
umber  of  yellow  plaques  per  vessel  is  associated  with  the
isk  of  ACS,  the  present  study  has  revealed  that  the  num-
er  of  yellow  plaques  per  vessel  is  also  associated  with  the
isk  of  silent  coronary  artery  stenosis  progression.  There-
ore,  angioscopically-determined  vulnerable  patients,  who
ave  high  risk  of  future  ACS  events,  also  have  high  risk  of
oronary  artery  stenosis  progression;  and  thus,  regression  of
ellow  plaques  would  be  a  hopeful  treatment  target  to  pre-
ent  both  ACS  and  coronary  artery  stenosis  progression.  It
as  remarkable  that  the  presence  of  multivessel  disease  was
ot  selected  as  a  signiﬁcant  risk  of  stenosis  progression  but
umber  of  yellow  plaques  was,  suggesting  that  the  extent
f  atherosclerosis  evaluated  by  luminal  stenosis  was  not  the
isk  of  further  stenosis  progression  but  that  evaluated  by  yel-
ow  plaques  was.  Because  statins  have  been  demonstrated
o  reduce  the  risk  of  ACS  events  and  to  induce  regression  of
ellow  plaques  [25]  by  prospective  clinical  trials,  statins  mayn  living  patients  achieved  by  clinical  studies  using  imag-
ng  modalities  such  as  angioscopy  [26]  and  OCT  [27]  have
ion  of  coronary  artery  stenosis.
Odds  ratio  (95%  CI)  p-value
1.05  (0.28—3.99)  0.941
1.44  (0.33—6.20)  0.629
1.91  (0.36—10.1)  0.447
1.65  (1.08—2.52)  0.020
0.88  (0.38—2.01)  0.755
ssel  0.81  (0.46—1.42)  0.452
>50% diameter stenosis by angiography.
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[2  
trengthened  the  hypothesis  that  the  formation  and  disrup-
ion  of  vulnerable  plaques  is  the  major  cause  of  coronary
therosclerosis  presented  as  ACS  and  stenosis  progression.
e  hope  the  ﬁndings  in  the  present  study  would  also  con-
ribute  to  this  purpose.
tudy  limitation
ecause  the  patients  with  successful  angioscopic  examina-
ion  were  included  and  those  who  had  coronary  arteries  not
uitable  for  angioscopic  examination  (e.g.  diffusely  stenotic
r  tortuous  coronary  arteries)  were  not  included,  there
hould  be  a  selection  bias.  The  sample  size  of  this  study
as  not  large  enough  to  analyze  multiple  factors  that  may
nduce  or  prevent  the  progression  of  coronary  artery  steno-
is,  and  thus  further  conﬁrmation  of  our  ﬁndings  might  be
equired.
onclusions
pproximately  30%  of  vulnerable  patients  with  ≥4  yellow
laques  per  vessel  had  coronary  artery  stenosis  progression
ithin  7  months.  Vulnerable  patients,  who  have  high  risk
f  future  ACS  events,  also  have  high  risk  of  coronary  artery
tenosis  progression.
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